Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance

Thrombosis Research

Volumn 141, Issue , 2016, Pages S68-S72

  Hoffmeister, Karin M ^a   Falet, Hervé ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ashwell Morell Receptor; glycans; JAK2; platelet clearance; STAT3; thrombopoietin

Indexed keywords

ACUTE PHASE PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; GLYCOPROTEIN GP 130; HEPATIC ASHWELL MORRELL RECEPTOR; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; REGULATOR PROTEIN; SIALIC ACID; STAT3 PROTEIN; THROMBOPOIETIN; UNCLASSIFIED DRUG; INTERLEUKIN 6 RECEPTOR;

ARTICLE; CELL AGING; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; ENDOCYTOSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER CELL; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY MECHANISM; SIALYLATION; THROMBOCYTE CLEARANCE; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; ANIMAL; CYTOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ASIALOGLYCOPROTEIN RECEPTOR; BLOOD PLATELETS; CELL AGING; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; THROMBOPOIETIN;

EID: 84989860946     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30370-X     Document Type: Article

References (62)

1. 1 Kaushansky, K, The molecular mechanisms that control thrombopoiesis. The Journal of clinical investigation 115 (2005), 3339–3347.
2. 2 Rumjantseva, V, Hoffmeister, KM, Novel and unexpected clearance mechanisms for cold platelets. Transfus Apher Sci 42 (2010), 63–70.
3. 3 Hoffmeister, KM, The role of lectins and glycans in platelet clearance. J Thromb Haemost 9:Suppl 1 (2011), 35–43.
4. 4 Grozovsky, R, Begonja, AJ, Liu, K, Visner, G, Hartwig, JH, Falet, H, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nature medicine 21 (2015), 47–54.
5. 5 Jansen, AJ, Josefsson, EC, Rumjantseva, V, Liu, QP, Falet, H, Bergmeier, W, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice. Blood 119 (2012), 1263–1273.
6. 6 Alioglu, B, Tasar, A, Ozen, C, Selver, B, Dallar, Y, An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report. Pathophysiol Haemost Thromb 37 (2010), 55–58.
7. 7 Shao, L, Wu, Y, Zhou, H, Qin, P, Ni, H, Peng, J, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets, 2014, 1–3.
8. 8 Jansen, AJ, Peng, J, Zhao, HG, Hou, M, Ni, H, Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia. Am J Hematol 90 (2015), E94–E95.
9. 9 Grewal, PK, The Ashwell-Morell receptor. Methods Enzymol 479 (2010), 223–241.
10. 10 Rumjantseva, V, Grewal, PK, Wandall, HH, Josefsson, EC, Sorensen, AL, Larson, G, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nature medicine 15 (2009), 1273–1280.
11. 11 Sorensen, AL, Rumjantseva, V, Nayeb-Hashemi, S, Clausen, H, Hartwig, JH, Wandall, HH, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 114 (2009), 1645–1654.
12. 12 Grewal, PK, Aziz, PV, Uchiyama, S, Rubio, GR, Lardone, RD, Le, D, et al. Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor. Proc Natl Acad Sci U S A, 2013.
13. 13 Grewal, PK, Uchiyama, S, Ditto, D, Varki, N, Le, DT, Nizet, V, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 14 (2008), 648–655.
14. 14 Crook, M, Platelet sialic Acid and its significance to platelet life-spans. Platelets, 1, 1990, 167.
15. 15 Crook, M, Sialic Acid: its importance to platelet function in health and disease. Platelets 2 (1991), 1–10.
16. 16 Reimers, HJ, Greenberg, J, Cazenave, JP, Packham, MA, Mustard, JF, Experimental modification of platelet survival. Adv Exp Med Biol 82 (1977), 231–233.
17. 17 Kaushansky, K, Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program, 2009, 147–152.
18. 18 Kuter, DJ, Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60 (2009), 193–206.
19. 19 Machlus, KR, Thon, JN, Italiano, JE Jr., Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol 165 (2014), 227–236.
20. 20 Bender, M, Giannini, S, Grozovsky, R, Jonsson, T, Christensen, H, Pluthero, FG, et al. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development. Blood 125 (2015), 1014–1024.
21. 21 Zhang, L, Orban, M, Lorenz, M, Barocke, V, Braun, D, Urtz, N, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med 209 (2012), 2165–2181.
22. 22 Kaushansky, K, Thrombopoiesis. Semin Hematol 52 (2015), 4–11.
23. 23 Kuter, DJ, Rosenberg, RD, The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85 (1995), 2720–2730.
24. 24 Cohen-Solal, K, Villeval, J, Titeux, M, Lok, S, Vainchenker, W, Wendling, F, Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 88 (1996), 2578–2628.
25. 25 Fielder, PJ, Gurney, AL, Stefanich, E, Marian, M, Moore, MW, Carver-Moore, K, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87 (1996), 2154–2161.
26. 26 Shinjo, K, Takeshita, A, Nakamura, S, Naitoh, K, Yanagi, M, Tobita, T, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia 12 (1998), 295–300.
27. 27 Engel, C, Loeffler, M, Franke, H, Schmitz, S, Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol 105 (1999), 832–838.
28. 28 Hitchcock, IS, Chen, MM, King, JR, Kaushansky, K, YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 112 (2008), 2222–2231.
29. 29 Ihara, K, Ishii, E, Eguchi, M, Takada, H, Suminoe, A, Good, RA, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 96 (1999), 3132–3136.
30. 30 Ballmaier, M, Germeshausen, M, Schulze, H, Cherkaoui, K, Lang, S, Gaudig, A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97 (2001), 139–146.
31. 31 Ballmaier, M, Schulze, H, Strauss, G, Cherkaoui, K, Wittner, N, Lynen, S, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 90 (1997), 612–619.
32. 32 Schrezenmeier, H, Griesshammer, M, Hornkohl, A, Nichol, JL, Hecht, T, Heimpel, H, et al. Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission. Br J Haematol 100 (1998), 571–576.
33. 33 Gu, J, Lu, L, Xu, R, Chen, X, Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chinese medical journal 115 (2002), 983–986.
34. 34 Ng, AP, Kauppi, M, Metcalf, D, Hyland, CD, Josefsson, EC, Lebois, M, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proceedings of the National Academy of Sciences of the United States of America 111 (2014), 5884–5889.
35. 35 Meyer, SC, Keller, MD, Woods, BA, LaFave, LM, Bastian, L, Kleppe, M, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood 124 (2014), 2280–2284.
36. 36 Kosugi, S, Kurata, Y, Tomiyama, Y, Tahara, T, Kato, T, Tadokoro, S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 93 (1996), 704–706.
37. 37 Ichikawa, N, Ishida, F, Shimodaira, S, Tahara, T, Kato, T, Kitano, K, Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 76 (1996), 156–160.
38. 38 Wang, JC, Chen, C, Novetsky, AD, Lichter, SM, Ahmed, F, Friedberg, NM, Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 104 (1998), 451–455.
39. 39 Griesshammer, M, Hornkohl, A, Nichol, JL, Hecht, T, Raghavachar, A, Heimpel, H, et al. High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production?. Ann Hematol 77 (1998), 211–215.
40. 40 Besancenot, R, Chaligne, R, Tonetti, C, Pasquier, F, Marty, C, Lecluse, Y, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS biology, 2010, 8.
41. 41 Pecquet, C, Diaconu, CC, Staerk, J, Girardot, M, Marty, C, Royer, Y, et al. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood 119 (2012), 4625–4635.
42. 42 McCarty, J, Sprugel, K, Fox, N, Sabath, D, Kaushansky, K, Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 86 (1995), 3668–3875.
43. 43 Sungaran, R, Chisholm, OT, Markovic, B, Khachigian, LM, Tanaka, Y, Chong, BH, The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood 95 (2000), 3094–3101.
44. 44 Mouthon, M, Vandamme, M, Gourmelon, P, Vainchenker, W, Wendling, F, Preferential liver irradiation enhances hematopoiesis through a thrombopoietin-independent mechanism. Radiat Res 152 (1999), 390–397.
45. 45 Sungaran, R, Markovic, B, Chong, B, Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 89 (1997), 101–107.
46. 46 Qian, S, Fu, F, Li, W, Chen, Q, de Sauvage, F, Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 92 (1998), 2189–2191.
47. 47 Wolber, EM, Ganschow, R, Burdelski, M, Jelkmann, W, Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 29 (1999), 1739–1742.
48. 48 McIntosh, B, Kaushansky, K, Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol 36 (2008), 799–806.
49. 49 Wolber, EM, Fandrey, J, Frackowski, U, Jelkmann, W, Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost 86 (2001), 1421–1424.
50. 50 Kaser, A, Brandacher, G, Steurer, W, Kaser, S, Offner, FA, Zoller, H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98 (2001), 2720–2725.
51. 51 Stone, RL, Nick, AM, McNeish, IA, Balkwill, F, Han, HD, Bottsford-Miller, J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366 (2012), 610–618.
52. 52 Cerutti, A, Custodi, P, Duranti, M, Noris, P, Balduini, CL, Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 99 (1997), 281–284.
53. 53 Wolber, E, Jelkmann, W, Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 20 (2000), 499–506.
54. 54 Burmester, H, Wolber, EM, Freitag, P, Fandrey, J, Jelkmann, W, Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res 25 (2005), 407–413.
55. 55 Eulenfeld, R, Dittrich, A, Khouri, C, Muller, PJ, Mutze, B, Wolf, A, et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 91 (2012), 486–495.
56. 56 Levine, RL, Gilliland, DG, Myeloproliferative disorders. Blood 112 (2008), 2190–2198.
57. 57 LaFave, LM, Levine, RL, JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends in pharmacological sciences 33 (2012), 574–582.
58. 58 Park, SO, Wamsley, HL, Bae, K, Hu, Z, Li, X, Choe, SW, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One, 8, 2013, e59675.
59. 59 Grisouard, J, Hao-Shen, H, Dirnhofer, S, Wagner, KU, Skoda, RC, Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica 99 (2014), e52–e54.
60. 60 Alonzi, T, Maritano, D, Gorgoni, B, Rizzuto, G, Libert, C, Poli, V, Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 21 (2001), 1621–1632.
61. 61 Lesurtel, M, Graf, R, Aleil, B, Walther, D, Tian, Y, Jochum, W, et al. Platelet-derived serotonin mediates liver regeneration. Science 312 (2006), 104–107.
62. 62 Dalton, SR, Lee, SM, King, RN, Nanji, AA, Kharbanda, KK, Casey, CA, et al. Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice. Biochem Pharmacol 77 (2009), 1283–1290.